TORONTO, June 9, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS"
or the "Company") (TSX: HLS), a specialty pharmaceutical company
focused on central nervous system and cardiovascular markets,
announces that it will be participating in Renmark Financial
Communications Inc.'s live Virtual Non-Deal Roadshow Series to
discuss its latest investor presentation on June 10, 2021 at 10:00 AM
EDT (7:00 AM PDT). HLS
welcomes stakeholders, investors, and other individual followers to
register and attend this live event.
The event will feature Gilbert
Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer. The
Company's presentation will be followed by a live Q&A.
Investors interested in participating in this event will need to
register using the link below. As a reminder, registration for the
live event may be limited, but access to the replay after the event
will be on the Company's Investor website.
To ensure smooth connectivity, please access this link using the
latest version of Google Chrome.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a
specialty pharmaceutical company focused on the acquisition and
commercialization of late-stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products targeting the
central nervous system and cardiovascular therapeutic areas. HLS's
management team is composed of seasoned pharmaceutical executives
with a strong track record of success in these therapeutic areas
and at managing products in each of these lifecycle stages. For
more information, please visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.